Novo Nordisk Presents Analysis Comparing Semaglutide and Resmetirom in MASH Patients
Novo Nordisk presented an analysis comparing semaglutide and resmetirom in patients with MASH.
Related stories
KBR Reports Quarterly Results for Period Ended September 30
KBR reported results for the quarter ended September 30; no figures were provided.
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Alphabet Shares Fall 12%
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Teck Resources reports quarterly results for period ended September 30
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Portland General Electric Reports Quarterly Results
Portland General Electric reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
Appian Receives Preliminary IL5 Authorization for Defense Cloud
Appian said it received preliminary IL5 authorization for its Defense Cloud from the U.S. Department of War.
M impact | EQUITY | Oct 29, 2026, 01:34 PM UTC
West Pharmaceutical Services Reports Quarterly Results
West Pharmaceutical Services reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 01:33 PM UTC